Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | AOC2 | O75106 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18280257 | 0.85 | TP53 (0.45) | TP53MAPTGLP1RKCNH2PPARG | |
| SCHEMBL18148898 | 0.84 | MEN1 (0.45) | TP53MAPTAOC2GLP1RKCNH2 | |
| SCHEMBL18280256 | 0.83 | TP53 (0.44) | TP53MAPTPPARGMEN1HTT | |
| SCHEMBL18280253 | 0.80 | TNF (0.41) | TP53AOC2GLP1RKCNH2 | |
| SCHEMBL18815810 | 0.76 | INPPL1 (0.36) | TP53MAPT | |
| SCHEMBL18148904 | 0.76 | GALR3 (0.46) | KCNH2PPARGMEN1KMT2A | |
| SCHEMBL18815814 | 0.71 | DRD4 (0.44) | TP53MAPT | |
| SCHEMBL18815809 | 0.71 | TNF (0.41) | TP53 | |
| SCHEMBL21768464 | 0.71 | TBXA2R (0.38) | TP53MAPT | |
| SCHEMBL15552361 | 0.70 | AAK1 (0.42) | TP53MAPTPPARGMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080117-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | claimed |
| US-9890154-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-13 | — | — | US | claimed |
| EP-3080117-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-9890154-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-13 | — | — | US | disclosed |
| US-20160355509-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355509-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TP53 1678/4885MAPT 2097/4885AOC2 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.